EHA 2023 | Longitudinal findings from the KarMMa trial: improved QoL in patients treated with ide-cel
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of CAR-T cells in the treatment of patients with relapsed/refractory (R/R) multiple myeloma, highlighting patient-reported experiences with the use of idecabtagene vicleucel (ide-cel). Dr Munshi explains that patients treated with ide-cel not only have an improved progression-free and overall survival (PFS; OS), but also demonstrate an improvement in quality of life (QoL). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So CAR-T cells are important for responses, they are important for durability of response, especially in an advanced patient population. What we need to remember is that, when we do CAR-T currently, nothing else is given to patients, they’re treatment free. And so, the critical important question ends up being what’s the quality of life? And in this study, using ide-cel – which was the first CAR-T cell approved, with a very high response rate, 84% response rate, all comers were patients with six previous median lines of treatment – we looked at these patients’ quality of life...
So CAR-T cells are important for responses, they are important for durability of response, especially in an advanced patient population. What we need to remember is that, when we do CAR-T currently, nothing else is given to patients, they’re treatment free. And so, the critical important question ends up being what’s the quality of life? And in this study, using ide-cel – which was the first CAR-T cell approved, with a very high response rate, 84% response rate, all comers were patients with six previous median lines of treatment – we looked at these patients’ quality of life. And just to give a one line summary: post CAR-T cell, patients have significant improvement in their quality of life. They’re essentially without any treatment, and that’s the strength of this. And this is what our presentation is, that CAR-T not only gets a response, improves both for progression-free and overall survival, but it also provides improved quality of life.
Read more...
